“When I resist, we persist”

Resist and PersistWhen I resist, we persist.

Call for Action
September 28 
International Safe Abortion Day

Why do we fight for access to safe abortion?

Ensuring universal access to safe abortion is a fundamental human right, we cannot view it as only a “women’s issue.” It is a fundamental human right, which intersects with and is integral to realizing social, economic and reproductive justice. When individuals are able to access safe abortion, along with comprehensive sexuality education and a range of contraceptives, the social good outcomes are numerous – including plummeting maternal mortality and morbidity, and significantly reduced rates of STIs and teenage pregnancy. Other positive ripple effects include an increase in women and girls’ ability to continue education; increased gender equity and women’s empowerment; and reduced intergenerational transfers of poverty, among many other integral benefits.

What’s happening on the world stage?
We have been witnessing a number of alarming rollbacks regarding sexual and reproductive health and rights (SRHR). Some of the most recent rollbacks include:

Read more

Cancer Patients Before Profits

Patients before ProfitsTime for cancer patients to come before corporate profits.  By Manon Ress

On 26th Of May, the World Health Assembly adopted the long debated Resolution on Cancer Prevention and Control. This is an important step towards supporting countries to address this disease in order to achieve Universal Health Coverage (UHC).

Cancers are a leading cause of morbidity and mortality worldwide, with approximately 14 million new cases and 8.2 million cancer-related deaths in 2012, 70% of which occurred in low and middle income countries. These numbers are expected to increase as society ages and lifestyles change, particularly in developing countries. The societal cost, as measured by human potential loss and economic cost, is high.

In addition to prevention efforts, addressing cancer requires access to prevention and treatment but this goal cannot be achieved under the existing policies that shape the price of medicines.

Breast cancer is the most common cancer in women both in developed and developing countries. Women with positive gene “human epidermal growth factor receptor 2” (HER2) face serious challenges related to the high prices of two effective medicines.

Trastuzumab is marketed by Roche under the brand name Herceptin. In South Africa, a 12-month course of trastuzumab costs approximately ZAR 516,700 ($38,000) – or around 5 times the country’s average household income. Given its unaffordability, trastuzumab is not available in South Africa’s public health sector where more than 80 percent of the country’s population seek care. Moreover, high co-payments required by medical insurers to access treatment are simply unaffordable for many who use the private sector”. (See also this post)

Read more